The long-term outcomes seem to be favorable, although relapses can be seen in 20-30% of the cases with higher rates associated with concurrent NMDAR-IgG antibodies, AQP-4 antibodies [18], and tumor at the onset of symptoms [17,18]. The gene discussed is AQP4; the disease is neoplasm.